Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Perrigo (NY: PRGO )

25.32 -0.63 (-2.43%)
Official Closing Price Updated: 7:00 PM EST, Jan 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Perrigo

< Previous 1 2 3 4 Next >
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris. 
Via Benzinga
PRGO Stock Earnings: Perrigo Beats EPS, Misses Revenue for Q2 2024
PRGO stock results show that Perrigo beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Abbott Labs (ABT) Stock Falls on Baby Formula Ruling. What to Know.
ABT stock is in focus on ruling news. Abbott faced a suit last year over the closing of its Michigan plant resulting in a formula shortage. 
Via InvestorPlace
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
Perrigo Supports Customers through Tough Times, Supporting Shareholders through Changes
Via Benzinga
Preview: Perrigo's Earnings
Via Benzinga
Perrigo Supports Customers through Tough Times, Supporting Shareholders through Changes
Via Benzinga
AbbVie Appeals To Supreme Court Over Attorney-Client Privilege In 'Long-Standing' AndroGel Case
AbbVie petitions the U.S. Supreme Court to protect its corporate records, arguing a lower court ruling threatens attorney-client privilege. 
Via Benzinga
$20M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
FDA Approves Over-the-Counter Birth Control Pill. Is the Pill Maker's Stock Set to Soar?
Perrigo picked up a milestone regulatory win. 
Via The Motley Fool
PRGO Stock Earnings: Perrigo Beats EPS, Misses Revenue for Q1 2024
PRGO stock results show that Perrigo beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Disney To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
CVS Health's Zero-Cost Coverage Paves Way For OTC Birth Control Access
CVS Health expands coverage to include the first OTC birth control pill in the U.S., offering accessible contraception without prescription costs. Learn about this pivotal shift in reproductive... 
Via Benzinga
Hidden Gems: 3 Market Underdogs to Buy at Rock-Bottom Prices
While these underdogs stocks might not be on everyone’s radar, they may offer surprisingly robust upside potential. 
Via InvestorPlace
Around $2M Bet On Tile Shop Holdings? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
Stocks Mixed As Consumer Confidence Falls
Stocks are mixed midday, after the most recent batch of economic data. 
Via Talk Markets
OTC Medicine Player Perrigo Outlines Three-Year Cost Saving Plan, Posts Mixed Q4 Earnings
Perrigo Q4 2023 net sales reach $1.2 billion, up 0.1% YoY. Explore Project Energize for long-term growth. 
Via Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
Insiders bet big on these turnaround stocks
Insiders are buying Bally's, Delcath Systems and Perrigo while their shares are at historic lows and catalysts are ahead. 
Via MarketBeat
Topics Economy Initial Public Offering
Exposures Interest Rates Securities Market
Insiders Buying DENTSPLY SIRONA And 2 Other Stocks
Although U.S. stocks closed lower on Monday, there were a few notable insider trades. 
Via Benzinga
$1.8M Bet On This Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed slightly higher on Friday, there were a few notable insider trades. 
Via Benzinga
Personal Care Industry Poised For Growth: Analyst Initiates Coverage On These 3 Stocks
Piper Sandler analyst Korinne Wolfmeyer initiated coverage on several personal care stocks, noting that amid the present economic conditions, consumers are becoming more discerning in their spending. 
Via Benzinga
Perrigo Cuts Annual Guidance, This OTC Drug Firm Also Reports Mixed Q3 Earnings
Perrigo Company PLC (NYSE: PRGO) reported  
Via Benzinga
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
Cramer Says This AI Company 'Actually Lived Up To Their Hype': Stock Is Up 148% This Year
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Energy Transfer LP (NYSE: ET) is "good." 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
With a Big Catalyst in Hand, Is Perrigo Company a Buy?
Regulators just ruled that one of its products can be sold over the counter. 
Via The Motley Fool
PRGO Stock Alert: Perrigo Climbs on Landmark FDA Birth Control Decision
Perrigo (PRGO) stock is rising on Friday as investors react to the company's over-the-counter birth control pill getting FDA approval. 
Via InvestorPlace
First Birth Control Pill For OTC Use In US Lands FDA Approval
Perrigo Company plc (NYSE: PRGO) shares are trading higher after the FDA approved the company's Opill, a progestin-only daily oral contraceptive for over-the-counter  
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.